Aurora Cannabis, Inc. (TSX: ACB) announced the launch of a new business to business service this morning called Aurora Pro. The new company will be supporting ancillary services to licensed producers and licensed retailer to the cannabis industry.
Aurora Pro’s services plan to offer supporting infrastructure for companies, business to business consulting on a wide range of categories, and marketing and product expertise. The new company plans to offer its services via subscription based on an online website portal that will contain a backend support and customer service team.
The hope for this new business is to offer supporting services to businesses that essentially wants to focus on what they do best, whether its growing, selling, or everything in between.
Terry Booth, the company’s CEO said, “We believe that Aurora PRO will provide a compelling, reliable and easy to use option for producers that are seeking market access for their products, while providing retailers with a responsive partner to help establish, develop and fine tune their operations. In a market expected initially to be supply restricted, Aurora PRO partners will have significant competitive advantages that will help them build market share and customer loyalty.”
About Aurora Cannabis
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada. Aurora trades on the Canadian Securities Exchange under the symbol “ACB”.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…